Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Akebia Therapeutics, Inc. (AKBA)

Pharmaceutical Preparations

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

245 FIRST STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/20/2014

Market Cap

295,454,640

Shares Outstanding

188,390,000

Weighted SO

188,389,415

Total Employees

N/A

Upcoming Earnings

08/23/2024

Similar Tickers

PLX --.--%

CDTX --.--%

XFOR --.--%

MCRB --.--%

AVRO --.--%

CWBR --.--%

OCEA --.--%

ENVB --.--%

ELEV --.--%

Beta

0.7670

Last Div

0.0000

Range

0.78-2.48

Chg

-0.0350

Avg Vol

2951927

Mkt Cap

295454640

Exch

NASDAQ

Country

US

Phone

617 871 2098

DCF Diff

1.7054

DCF

-0.0054

Div Yield

0.0000

P/S

1.6932

EV Multiple

146.7557

P/FV

-8.7289

Div Yield %

0.0000

P/E

-7.2854

PEG

-0.1409

Payout

0.0000

Current Ratio

1.0447

Quick Ratio

0.8222

Cash Ratio

0.3681

DSO

62.2602

DIO

131.0583

Op Cycle

193.3185

DPO

55.4879

CCC

137.8307

Gross Margin

0.6190

Op Margin

-0.2021

Pretax Margin

-0.2318

Net Margin

-0.2318

Eff Tax Rate

-0.2645

ROA

-0.1837

ROE

1.2347

ROCE

-0.3124

NI/EBT

1.0000

EBT/EBIT

1.1468

EBIT/Rev

-0.2021

Debt Ratio

0.4465

D/E

-2.9130

LT Debt/Cap

1.5883

Total Debt/Cap

1.5228

Int Coverage

-11.1001

CF/Debt

-0.3964

Equity Multi

-6.5236

Rec Turnover

5.8625

Pay Turnover

6.5780

Inv Turnover

2.7850

FA Turnover

13.1646

Asset Turnover

0.7925

OCF/Share

-0.1858

FCF/Share

-0.1860

Cash/Share

0.5885

OCF/Sales

-0.2233

FCF/OCF

1.0007

CF Coverage

-0.3964

ST Coverage

-5.4189

CapEx Coverage

-1343.8966

Div&CapEx Cov

-1343.8966

P/BV

-8.7289

P/B

-8.7289

P/S

1.6932

P/E

-7.2854

P/FCF

-7.5754

P/OCF

-7.5600

P/CF

-7.5600

PEG

-0.1409

P/S

1.6932

EV Multiple

146.7557

P/FV

-8.7289

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 20, 02:17 Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Revenue Product Segmentation